Fig. 1From: Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomyKaplan-Meier curve for a CRPC-free survival and b OS categorized by PSAT½ Back to article page